Johnson & Johnson's Q3 2016 earnings call highlighted strong pharmaceutical performance, particularly in oncology and immunology, driven by new product success and market share gains.  Management expressed confidence in the company's ability to continue outpacing industry growth, even with biosimilar competition, due to its robust pipeline and focus on line extensions.  The call signals a positive outlook for the next few weeks, leaning towards a rally in the stock price given the strength of reported results and management's optimistic guidance.
[2]
